Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 7/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.54 |
| ▸ | CTSL | P07711 | 4/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11153005 | 0.92 | CTSL (0.61) | SMN1; SMN2CTSKMMEECE1CTSL | |
| SCHEMBL10192703 | 0.90 | KYNU (0.58) | SMN1; SMN2ALDH1A1ALOX15CTSKMME | |
| SCHEMBL10074198 | 0.90 | KYNU (0.58) | SMN1; SMN2ALDH1A1ALOX15CTSKMME | |
| SCHEMBL2083704 | 0.90 | KYNU (0.58) | SMN1; SMN2ALDH1A1ALOX15CTSKMME | |
| SCHEMBL716988 | 0.89 | MME (0.65) | SMN1; SMN2CTSKMMEECE1SIRT2 | |
| SCHEMBL10192704 | 0.89 | MME (0.65) | SMN1; SMN2CTSKMMEECE1SIRT2 | |
| SCHEMBL29682481 | 0.89 | MME (0.56) | SMN1; SMN2CTSKMMEECE1CTSL | |
| SCHEMBL716987 | 0.89 | MME (0.65) | SMN1; SMN2CTSKMMEECE1SIRT2 | |
| SCHEMBL4919347 | 0.89 | MME (0.56) | SMN1; SMN2CTSKMMEECE1CTSL | |
| SCHEMBL28993693 | 0.89 | MME (0.56) | SMN1; SMN2CTSKMMEECE1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | SMN1; SMN2 3267/4885ALDH1A1 4236/4885ALOX15 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.